Gene Therapy for Atrial Fibrillation

A gene therapy targeting oxidative stress and parasympathetic signaling using NOX2 shRNA and Gαi/o peptides effectively addresses the limitations of current AF treatments by preventing and reversing electrical remodeling, reducing AF recurrence and associated conditions.

JP7588414B2Active Publication Date: 2024-11-22NORTHWESTERN UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021542429
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-01-24
Filing Date
2020-01-24
Publication Date
2024-11-22
Estimated Expiration
2040-01-24

AI Technical Summary

Technical Problem

Current treatments for atrial fibrillation, including pharmacological and ablative methods, are suboptimal for patients with persistent AF, as they do not target the key molecular mechanisms underlying the disease, leading to incomplete blockage of the underlying disease process.

Method used

A gene therapy approach involving the inhibition of oxidative stress (OS) and parasympathetic nervous system signaling through the use of NOX2 shRNA and Gαi2/Gαo1 inhibitory peptides, administered via electroporation, to prevent and reverse electrical remodeling in the heart.

Benefits of technology

This approach effectively prevents and reverses atrial fibrillation by targeting fundamental mechanisms, reducing AF recurrence and associated conditions such as stroke and heart failure, with NOX2 shRNA and Gαi/o peptides showing synergistic effects in preventing electrical remodeling and nerve sprouting.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588414000002
    Figure 0007588414000002
  • Figure 0007588414000003
    Figure 0007588414000003
  • Figure 0007588414000004
    Figure 0007588414000004
Patent Text Reader

Abstract

Provided herein are compositions, methods, and devices for treating and preventing atrial fibrillation (AF) using gene therapy techniques. Specifically, oxidative stress (OS) and parasympathetic nervous system signaling are inhibited, thereby preventing and / or reversing the electrical remodeling that underlies AF.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] [Technical field] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 796,421, filed January 24, 2019, which is incorporated by reference in its entirety.

[0002] Provided herein are compositions, methods, and devices for treating and preventing atrial fibrillation (AF) using gene therapy techniques. Specifically, oxidative stress (OS) and parasympathetic nervous system signaling are inhibited to prevent and / or reverse the electrical remodeling that underlies AF.

[0003] [Background technology] Atrial fibrillation (AF) is the most common cardiac rhythm disorder. AF affects over 6 million Americans and is the leading cause of stroke. AF is primarily an age-related disease and is therefore rapidly becoming more prevalent in an aging population. Unfortunately, current treatments for AF, both pharmacological and ablation methods, are suboptimal for patients with persistent AF. Ablation is considered the "gold standard" for treating AF today and has been moderately successful in patients with paroxysmal AF (70-75% success rate) (Reference 1; the disclosure of which is incorporated herein by reference in its entirety), but has a suboptimal success rate in patients with persistent AF (less than 50%) (References 2-4; the disclosures of which are incorporated herein by reference in their entirety).

[0004] NADPH oxidase 2 (Nox2), also known as cytochrome b(558) subunit β or cytochrome b-245 heavy chain, is a protein encoded by the NOX2 gene (also called CYBB) in humans.[5] This protein is a superoxide-generating enzyme that generates reactive oxygen species (ROS).

[0005] G iThe G protein α subunits are a family of heterotrimeric G protein α subunits. This family is also commonly referred to as G, including closely related family members. i / o (G i / G o ) Family or G i / o / z / t The Gα subunit is also called the G family. i Alpha, G αi , or G i It is sometimes called α.

[0006] Summary of the Invention Provided herein are compositions, methods, and devices for treating and preventing atrial fibrillation (AF) using gene therapy techniques. Specifically, oxidative stress (OS) and parasympathetic nervous system signaling are inhibited to prevent and / or reverse the electrical remodeling that underlies AF.

[0007] In some embodiments, provided herein are methods of treating atrial fibrillation (AF), comprising inhibiting / reducing oxidative stress (OS) and parasympathetic nervous system signaling via a gene therapy approach. In some embodiments, the gene therapy approach comprises administration of a transgene to a subject suffering from or at risk for AF. In some embodiments, the gene therapy approach comprises administration of a NOX2 shRNA, and / or Gα i2 and Gα o1 The method comprises administering one or both of the inhibitory peptides. In some embodiments, the gene therapy approach comprises electroporation.

[0008] In some embodiments, provided herein is a method of preventing or reversing cardiac electrical remodeling and / or atrial fibrillation in a subject, comprising administering to the subject an effective amount of (a) an NADPH oxidase 2 (NOX2) inhibitor, and / or (b)(i) a Gα i inhibitory peptides, and / or (ii) Gα oThe present invention provides a method comprising administering an inhibitory peptide to a subject, the administering being performed under conditions such that the level of cardiac electrical remodeling and / or atrial fibrillation is prevented, reduced, or eliminated. In some embodiments, the NOX2 inhibitor is a nucleic acid inhibitor of NOX2 gene expression. In some embodiments, the nucleic acid inhibitor of NOX2 gene expression is a NOX2 siRNA. In some embodiments, the nucleic acid inhibitor of NOX2 gene expression is a NOX2 shRNA. In some embodiments, the NOX2 shRNA has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or a range therebetween) sequence identity to SEQ ID NO:34. In some embodiments, the NOX2 shRNA is provided on a vector that has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any range therebetween) sequence identity to SEQ ID NO:2. i The inhibitory peptide is Gα i2 In some embodiments, the inhibitory peptide is a Gα i The inhibitory peptide is a C-terminal Gα i In some embodiments, the Gαo inhibitory peptide is a Gα o1 In some embodiments, the inhibitory peptide is a Gα o The inhibitory peptide is a C-terminal Gα o In some embodiments, the inhibitory peptide is a Gα i Inhibitory peptides and / or Gα o The inhibitory peptide is administered as and expressed from a minigene. In some embodiments, the minigene is present on a plasmid. In some embodiments, the Gα i The inhibitory peptide has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or a range therebetween) sequence identity to SEQ ID NO:3. oThe inhibitory peptide has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or a range therebetween) sequence identity to SEQ ID NO:4. i Inhibitory peptides and Gα o In some embodiments, the inhibitory peptide is co-administered. i Inhibitory peptides and Gα o The inhibitory peptide is co-administered at a ratio of 1:10 to 10:1 (e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or ranges therebetween). In some embodiments, the NOX2 inhibitor is a Gα i Inhibitory peptides and / or Gα o In some embodiments, the inhibitor is administered simultaneously with a NOX2 inhibitor, a Gα i Inhibitory peptides and Gα o In some embodiments, the inhibitory peptide is co-administered. i Inhibitory peptides and / or Gα o The inhibitory peptide is administered to the myocardial tissue. In some embodiments, the method further comprises electroporating the tissue before, during, or after administration. In some embodiments, the myocardial tissue comprises at least one of atrial tissue or ventricular tissue. In some embodiments, the NOX2 inhibitor, Gα i Inhibitory peptides and / or Gα o The inhibitory peptide is administered endocardially or epicardially. In some embodiments, the NOX2 inhibitor, Gα i Inhibitory peptides and / or Gα o The inhibitory peptide is administered to a segment of the coronary vasculature of the subject, and the target coronary tissue of the subject is electroporated. i Inhibitory peptides and / or Gα o Administration of inhibitory peptides to subjects results in NOX2 inhibitors, Gα iInhibitory peptides and / or Gα o In some embodiments, the method comprises administering an effective amount of a NOX2 inhibitor, a Gα i Inhibitory peptides and / or Gα o Administering the inhibitory peptide to the subject comprises injecting isolated therapeutic DNA.In some embodiments, the subject suffers from one or more of atrial or ventricular arrhythmia, ventricular failure, or heart failure.In some embodiments, the arrhythmia comprises atrial fibrillation.

[0009] In some embodiments, the present invention provides a method for treating a gastric cancer comprising: (a) an NADPH oxidase 2 (NOX2) inhibitor; (b)(i) a Gα i Inhibitory peptides or Gα i (ii) a nucleic acid encoding an inhibitory peptide; and / or o Inhibitory peptides or Gα o A pharmaceutical composition is provided that includes a nucleic acid encoding an inhibitory peptide. In some embodiments, the NOX2 inhibitor is a nucleic acid inhibitor of NOX2 gene expression. In some embodiments, the nucleic acid inhibitor of NOX2 gene expression is a siRNA of NOX2. In some embodiments, the nucleic acid inhibitor of NOX2 gene expression is a NOX2 shRNA. In some embodiments, the NOX2 shRNA has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any range therebetween) sequence identity to SEQ ID NO:34. In some embodiments, the NOX2 shRNA is provided on a vector that has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any range therebetween) sequence identity to SEQ ID NO:2 ... i The inhibitory peptide is Gα i2 In some embodiments, the inhibitory peptide is a Gα i The inhibitory peptide is a C-terminal Gα iIn some embodiments, the Gαo inhibitory peptide is a Gα o1 In some embodiments, the inhibitory peptide is a Gα o The inhibitory peptide is a C-terminal Gα o In some embodiments, the inhibitory peptide is a Gα o The nucleic acid encoding the inhibitory peptide comprises a minigene. o The nucleic acid encoding the inhibitory peptide is a plasmid. i The nucleic acid encoding the inhibitory peptide comprises a minigene. i The nucleic acid encoding the inhibitory peptide is a plasmid. i The inhibitory peptide has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any range therebetween) sequence identity to SEQ ID NO:3. O The inhibitory peptide has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or ranges therebetween) sequence identity to SEQ ID NO:4. i Inhibitory peptides and Gα o In some embodiments, the pharmaceutical composition comprises both a Gα inhibitory peptide and a Gα i A nucleic acid encoding an inhibitory peptide and Gα o In some embodiments, the nucleic acid encoding the Gα inhibitory peptide is i Inhibitory peptides and / or Gα i A nucleic acid encoding an inhibitory peptide and Gα o Inhibitory peptides and / or Gα o The nucleic acids encoding the inhibitory peptides are present in a ratio of 1:10 to 10:1 (e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or ranges therebetween).

[0010] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1] RAP leads to increased nerve hypertrophy and sprouting of parasympathetic fibers.

[0011] [Figure 2] Chronic expression of NOX2 shRNA prevents AF in RAP.

[0012] [Figure 3] NOX2 shRNA prevents neuronal hyperplasia and parasympathetic sprouting in the RAP.

[0013] [Figure 4] Gαi / o minigene delays the time to onset of AF in RAP.

[0014] [Figure 5A] NOX2 shRNA prevents the development of persistent AF. In short-term studies, animals treated with NOX2 shRNA developed significantly shorter AF, with a delay in the onset of persistent AF of more than 30 minutes. For control, N=3-12; for NOX2 shRNA, n=3-5.

[0015] [Figure 5B] NOX2 shRNA prevents the development of persistent AF. In our long-term study, gene injection of NOX2 shRNA prevented the onset of persistent AF for longer than 8 hours. In A and B, control, n=3-12, NOX2 shRNA, n=3-7. Data are means ± SEM. Significant differences by log-rank test are shown on the graph.

[0016] [Figure 6] Decreased NOX2 expression in NOX2 shRNA-transfected atria.

[0017] [Figure 7] Reduction of atrial fibrosis by NOX2 shRNA.

[0018] [Figure 8] NOX2 shRNA±Gαi / o converts AF to atrial flutter or synchrony. For discussion, see text.

[0019] FIG. 9. Exemplary amino acid sequences of modified carboxy-terminal Gα peptides.

[0020] FIG. 10. Nucleotide sequence of an exemplary minigene of the present invention.

[0021] [Mode for carrying out the invention] definition Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of each embodiment described herein, some preferred methods, compositions, devices, and materials are described herein. However, prior to describing the materials and methods, it should be understood that the present invention is not limited to the specific molecules, compositions, methodologies, or protocols described herein, as these may vary according to routine experimentation and optimization. It should also be understood that the terminology used in the description is intended to describe only the particular forms or embodiments, and is not intended to limit the scope of the embodiments described herein.

[0022] Unless otherwise defined, all technical and scientific terms used herein shall have the same meaning as commonly understood by those skilled in the art to which this invention belongs. However, in case of conflict, the present specification including definitions shall prevail. Therefore, in the context of the embodiments described herein, the following definitions shall apply.

[0023] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a minigene" refers to one or more minigenes and equivalents thereof known to those skilled in the art.

[0024] As used herein, the term "about," when referring to a value, is intended to encompass variations in some embodiments of ±20%, in some embodiments of ±10%, in some embodiments of ±5%, in some embodiments of ±1%, in some embodiments of ±0.5%, and in some embodiments of ±0.1% from the indicated amount, as such variations are appropriate in practicing the disclosed methods.

[0025] As used herein, the term "comprise" and linguistic variations thereof indicate the presence of the recited feature(s), element(s), method step(s), etc., without excluding the presence of additional feature(s), element(s), method step(s), etc. In contrast, the term "consisting of" and linguistic variations thereof indicate the presence of the recited feature(s), element(s), method step(s), etc., but excluding any unrecited feature(s), element(s), method step(s), etc., except for impurities normally associated therewith. The phrase "consisting essentially of" indicates the recited feature(s), element(s), method step(s), etc., as well as any additional feature(s), element(s), method step(s), etc. that do not substantially affect the basic nature of the composition, system, or method. Many embodiments herein are described using the open term "comprise." Such embodiments encompass several closed "consisting of" and / or "consisting essentially of" embodiments, which may alternatively be claimed or described using such terms.

[0026] As used herein, the term "subject" refers to any animal, including, but not limited to, insects, humans, non-human primates, vertebrates, cows, horses, cats, dogs, pigs, rodents, etc. The terms "subject" and "patient" may be used interchangeably. A subject may be at any stage of life (e.g., embryo, fetus, infant, newborn, child, adult, etc.). A subject may be male or female.

[0027] As used herein, the terms "treat", "treatment", and "treating" refer to reducing the amount or severity of a particular condition or disease state (e.g., cardiovascular disorder) in a subject currently suffering from or afflicted with the condition, disease state, or symptoms thereof. These terms do not necessarily indicate a complete cure (e.g., complete disappearance of the condition, disease, or symptoms thereof). "Treatment" encompasses any administration or application of a therapeutic agent or technique to a disease (e.g., in a mammal, including a human), including inhibiting a disease, preventing its onset, relieving a disease, inducing regression, or restoring or repairing lost, deficient, or defective function, or stimulating an inefficient process.

[0028] As used herein, the term "treat" and its linguistic variants include therapeutic measures, whereas the term "prevent" and its linguistic variants include prophylactic measures, unless otherwise indicated.

[0029] The phrases "small hairpin RNA" and the term "shRNA" as used herein refer to a single RNA-containing polynucleotide capable of performing RNAi (RNA interference) and comprising a sense sequence, a loop, and an antisense sequence. The sense sequence and the antisense sequence may be referred to herein as a first region and a second region. As described herein, the sense sequence and the antisense sequence may have different orientations in the shRNA of the present invention (L or R shRNA). Thus, if the first region of the shRNA is a sense sequence, the second region is an antisense region, and vice versa. Preferably, the sense sequence and the antisense sequence are substantially complementary to each other (about 80% complementary). The antisense sequence may be about 16 to about 22 nucleotides in length, for example, about 16 to 19 nucleotides in length, more preferably 18 to 19 nucleotides in length. The sense sequence may be about 11 to about 22 nucleotides in length, more preferably 17 to 19 nucleotides in length. An shRNA (and other RNAi agents) is "specific" for a target gene if the antisense sequence (of about 16-22 nucleotides) is substantially complementary to the target gene (or target RNA, e.g., target mRNA). Substantially complementary means that the antisense sequence is at least 80% complementary to the target gene (or gene product). Thus, in some embodiments, an antisense sequence that is complementary to a target gene may contain mismatches to the target. The sequence can be modified to target one or more genetic variants or phenotypes of a target, e.g., a viral target, by modifying the targeting sequence to be complementary to the sequence of the genetic variant or phenotype. The shRNA may have a loop, e.g., 0 to about 24 nucleotides in length, preferably 0 to about 10 nucleotides in length, 0 to 6 nucleotides in length, e.g., 2 nucleotides in length. The sequence of the loop may include nucleotide residues unrelated to the target. In a particularly preferred embodiment, the loop is 5'-UU-3'. In some embodiments, the loop may include a non-nucleotide portion. In still other embodiments, the loop does not include a non-nucleotide portion.Optionally, the shRNA can have a 2-base overhang region at the 3' end of the molecule. The shRNA can also include RNAs having a stem-loop structure that includes mismatches and / or bulges. The sense sequence that is homologous to the target can differ at about 0 to about 5 sites, for example, by having about 1 to about 5 nucleotide mismatches, insertions, or deletions, as in the case of naturally occurring microRNAs. RNAs that include any of the above structures can include structures in which the loop includes nucleotides, non-nucleotides, or a combination of nucleotides and non-nucleotides.

[0030] Additionally, the phrases "short hairpin RNA" and the term "shRNA" include nucleic acids that contain moieties other than ribonucleotide moieties, including, but not limited to, modified nucleotides, modified internucleotide linkages, non-nucleotides, deoxynucleotides, and analogs of the above nucleotides. Descriptions of modified shRNAs of interest may be found in the following references, all of which are incorporated herein by reference in their entireties: Namely, Q. Ge, H. Ilves, A. Dallas, P. Kumar, J. Shorenstein, SA Kazakov, and BH Johnston (2010) Minimal-length short hairpin RNAs: The Relationship of Structure and RNAi Activity. RNA16(1):106-17 (Epub and Q. Ge, A. Dallas, H. Ilves, J. Shorenstein, MABehlke, and BH Johnston (2010) Effects of Chemical Modification on the Potency, Serum Stability, and Immunostimulatory Properties of Short shRNAs.RNA 16(1):118-30 (Epub Nov. 30, 2009).

[0031] As used herein, the phrase "antisense sequence" refers to a polynucleotide or a region of a polynucleotide that is substantially complementary (e.g., 80% or more) or 100% complementary to a target nucleic acid of interest. An antisense sequence may be composed of a polynucleotide region that is RNA, DNA, or a chimeric RNA / DNA. Any nucleotide in an antisense sequence may be modified by having a substituent attached to the nucleotide, such as in a 2' modification. An antisense sequence may be modified with a variety of groups of small molecules and / or conjugates. For example, an antisense sequence may be fully or partially complementary to a molecule of messenger RNA, a non-mRNA RNA sequence (e.g., tRNA, rRNA, hnRNA, - and + strand viral RNA and its complementary RNA), or a sequence of DNA, either a coding or non-coding sequence.

[0032] As used herein, the phrase "sense sequence" refers to a polynucleotide or region having a nucleotide sequence that is wholly or partially the same as a target nucleic acid, such as a sequence of messenger RNA or DNA. By convention, when a sequence is given, unless otherwise indicated, that sequence is the sense sequence (or region) and the presence of a complementary antisense sequence (or region) is implicit.

[0033] As used herein, the term "complementary" refers to the ability of polynucleotides to base pair with one another. Base pairs are usually formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands or regions. Complementary polynucleotide strands or regions can base pair in a Watson-Crick fashion (e.g., A with T, A with U, C with G), or in any other fashion that allows for the formation of a stable duplex.

[0034] As used herein, "perfect complementarity" or "100% complementarity" refers to a situation in which each nucleotide unit of one polynucleotide strand or region can hydrogen bond with each nucleotide unit of a second polynucleotide strand or region. Less than perfect complementarity refers to a situation in which some, but not all, nucleotide units of two strands or two regions can hydrogen bond with each other. For example, in two 19-mers, if 17 base pairs of each strand or region can hydrogen bond with each other, the polynucleotide strands exhibit 89.5% complementarity. Substantial complementarity refers to polynucleotide strands or regions that exhibit about 80% or more complementarity.

[0035] As used herein, the term "pharmaceutically acceptable" refers to a carrier, diluent, excipient, and / or salt that is compatible with the other ingredients of the formulation, but not deleterious to the recipient thereof. The active ingredient to be administered may be present as a powder or granules, as a solution, suspension or emulsion, or as described elsewhere throughout this specification.

[0036] The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable salt, solvent, suspension or vehicle for delivering the composition of the present disclosure to animals or humans. Carriers can be liquid, semi-solid or solid, and are often used synonymously with diluents, excipients or salts. The phrase "pharmaceutically acceptable" means that the disclosed ingredient, excipient, carrier, diluent or ingredient is suitable for use in humans and / or animals without undue adverse side effects (toxicity, irritation, allergic reaction, etc.) commensurate with a reasonable benefit / risk ratio. See Remington's Pharmaceutical Sciences 16.sup.th edition, Osol, A.Ed (1980), the disclosure of which is incorporated herein by reference in its entirety.

[0037] As used herein, the term "minigene" refers to a minimal gene fragment that does not contain one or more elements of a native locus, but contains the elements required for expression of a gene product or a portion of a gene product, or a synthetic construct.

[0038] The main reason current therapies are not successful is because they do not target the key molecular mechanisms underlying AF and therefore do not interrupt the underlying disease process. AF is a multifactorial disease with several key underlying molecular mechanisms. Current drugs and ablations do not target the key molecular mechanisms and therefore do not interrupt the underlying disease process.

[0039] Experiments conducted during the development of embodiments herein have shown that NOX2 shRNA completely prevents electrical remodeling and AF induced by rapid atrial pacing (RAP). NOX2 shRNA can also prevent atrial fibrosis in HF models. Parasympathetic inhibition (by Gαi / o-ct) also significantly inhibited electrical remodeling and AF induced by RAP. NOX2 shRNA inhibited parasympathetic sprouting in RAP-treated dogs, indicating a significant interplay between oxidative damage and parasympathetic signaling in the formation of electrical remodeling in AF. Furthermore, experiments have demonstrated that NOX2 shRNA can reverse electrical remodeling in RAP-treated dogs with established AF, especially when administered in combination with Gαi / o-ct.

[0040] Provided herein are approaches to the treatment and prevention of AF that target one or more key molecular mechanisms underlying the development of AF pathology. Certain embodiments herein target fundamental mechanisms that contribute to electrical remodeling in AF, such as oxidative stress (OS), parasympathetic nervous system signaling, etc. In some embodiments, provided herein are gene therapy approaches to inhibit OS and parasympathetic signaling in one or both atria. In some embodiments, this approach reduces AF in patients resistant to ablation by directly targeting two key molecular mechanisms underlying electrical remodeling in AF.

[0041] In some embodiments, provided herein is direct atrial injection of transgene(s) targeting OS and / or parasympathetic signaling to reverse established substrates of AF. In some embodiments, the gene targeting OS is NOX2 shRNA. In some embodiments, the gene targeting parasympathetic signaling is Gα i2 and Gα o1 The experiments carried out during the development of the embodiments herein included either or both of the NOX2 shRNA and Gα inhibitor peptides. i2 / Gα o1 Both peptides have been shown to prevent electrical remodeling in a rapid atrial pacing (RAP) canine model of AF, resulting in a reduction in AF. Experiments conducted during the development of the embodiments herein also indicate that these mechanisms are closely interrelated, with OS contributing at least in part to electrical remodeling in AF by causing atrial parasympathetic thickening / sprouting. In some embodiments, the ability of the approaches herein to reverse established AF substrates provides a therapeutic effect of this technology. In some embodiments, the embodiments herein modify the disease state of AF, restoring sinus rhythm and resulting in a reduction in AF-related stroke, heart failure, and the like.

[0042] In some embodiments, the therapeutic agent is administered epicardially by a surgeon during open heart surgery to perform coronary artery bypass or valve replacement, hi some embodiments, a less invasive transvenous endocardial approach is used.

[0043] Experiments conducted during the development of embodiments herein have identified fundamental mechanisms in the formation of the atrial fibrillation (AF) disease state (References 8-10; the disclosures of which are incorporated herein by reference in their entireties) and several transgenes that can selectively target these mechanisms in the atria (References 10-11; the disclosures of which are incorporated herein by reference in their entireties). Some embodiments herein target a combination of two fundamental mechanisms that contribute to electrical remodeling, oxidative stress, and parasympathetic nervous system signaling in AF. In some embodiments, vectors (e.g., plasmids) are used that express the following transgenes: (a) NOX2 shRNA (this gene inhibits NOX2, the major enzymatic contributor to oxidative stress), and (b) C-terminal Gα i +Gα o Inhibitory peptides (e.g., in a 1:1 ratio), which inhibit parasympathetic atrial signaling. In some embodiments, the therapeutic agent is a NOX2 shRNA ± (Gα i +Gα o plasmid).

[0044] During the development of the embodiments herein, experiments were performed to demonstrate that a transgene (plasmid) can be successfully expressed in the atrium by using electroporation in a clinically relevant large animal model of AF, resulting in a reduction in AF. The effectiveness of the approach to prevent electrical remodeling of AF is described below. During the development of the embodiments herein, experiments are performed to demonstrate that the transgene reverses the established AF substrate. Since studies have shown evidence of significant crosstalk, and even synergy, between OS and parasympathetic signaling in the formation of a vulnerable AF substrate, during the development of the embodiments herein, NOX2 shRNA and Gα i / o Experiments are performed to demonstrate that administration of inhibitory peptides, alone or in combination, reverses established AF substrates.

[0045] ROS generated by NOX2 are elevated in atria undergoing RAP. Four dogs underwent RAP at 600 bpm for 3-4 weeks (without ablation of the atrioventricular node) (Ref. 13, the disclosure of which is incorporated herein by reference in its entirety). PLAs from dogs undergoing RAP and five normal (control) dogs were cultured in the presence of different ROS inhibitors. 2- The production of total O was assessed (for NOX2, mitochondrial ROS, xanthine oxidase, and NOS) (Reference 14, the disclosure of which is incorporated herein by reference in its entirety). 2- was significantly increased in RAP PLA, and NOX2 was found to be the major factor in the total O 2- (3-fold increase above normal; P<0.05). 2- The increase in mitochondrial induction of O was accompanied by a more than 10-fold increase in gp91 (the major NOX2 subunit) expression in RAP atria compared to controls (p<0.01). 2- Conclusions: NOX2-generated OS was also elevated in RAP (1.5-fold increase above normal; p<0.05). NOX2-generated OS was significantly elevated in the setting of electrical remodeling in AF, indicating that OS may be a viable therapeutic target in AF.

[0046] AF causes nerve hyperplasia and parasympathetic / sympathetic sprouting in the left atrium (References 8, 15; the disclosures of which are incorporated herein by reference in their entireties). The RAP model was established in five animals by RAP at 600 beats per minute for 3-4 weeks (without ablation of the atrioventricular node). Five normal dogs served as controls. PLA and LAA sections were examined for parasympathetic and sympathetic nerves (acetylcholinesterase, dopamine β-hydroxylase). Nerve growth factor (NGF) expression was assessed by PCR. The PLA revealed unique thick nerve bundles (>0.01 mm ) that were not seen in the LAA in both RAP and control animals. 2 ) In RAP compared with controls, i) the nerve bundles in the PLA were significantly thicker and ii) parasympathetic fibers predominated (Figure 1). Sympathetic fibers were also increased in RAP (4.8 fibers / mm vs. 2.4). 2 , p<0.05). The proliferation of parasympathetic and sympathetic nerves correlated with increased NGF expression in the RAP GP (>10-fold increase; p<0.01). Thus, RAP induces marked nerve thickening and an increase in parasympathetic and sympathetic fibers in the PLA.

[0047] NOX2 shRNA suppresses ERP shortening / AF and parasympathetic sprouting in atria subjected to RAP. Experiments were performed during development of embodiments herein to demonstrate that knockdown of NOX2 in PLA myocardium + GP (4 weeks) not only suppresses ERP shortening induced by RAP but also suppresses RAP-induced nerve proliferation / sprouting. In three animals, 10 mg of plasmid expressing NOX2 shRNA was injected subepicardially into the PLA followed by electroporation to facilitate gene delivery. Seven control animals were also subjected to RAP (one was injected with a scrambled gene, one was a sham control, and the others underwent RAP without thoracotomy). One week after gene injection, gene-injected animals were subjected to RAP at 600 bpm for 20 days (without atrioventricular node ablation) and then terminal testing. Pacing was stopped for each animal every 48 hours for 30-60 minutes to assess spontaneous AF (defined as AF that did not terminate during this time). After the final test, NOX2 was measured (PCR, Western blotting), NGF expression was evaluated (PCR), and autonomic nerves were stained. Figure 2 shows that control dogs (scrambled gene and sham) developed persistent AF after 6 days of RAP. In contrast, no significant AF was observed in animals treated with NOX2 shRNA (NOX2 shRNA vs. control, p<0.05; Figure 2). ERPs were significantly longer in dogs treated with NOX2 shRNA compared to controls (124±25 ms vs. <50 ms; p<0.05). NOX2 levels were significantly reduced by NOX2 shRNA by PCR (50% reduction, p<0.05) and Western blotting. NGF was reduced in PLAs injected with NOX2 shRNA (approximately 50% knockdown; p<0.05). Immunostaining showed that NOX2 shRNA-injected PLAs did not show thickening of nerve bundles, whereas RAP controls showed parasympathetic overinnervation (Figure 3). NOX2 shRNA prevents ERP shortening and AF in RAP. NOX2 inhibition also suppresses RAP-induced parasympathetic proliferation.OS-induced parasympathetic proliferation may be an important mechanism contributing to ERP shortening during RAP.

[0048] After gene injection, even after 7 months of continuous RAP, none of the canine subjects developed AF (only atrial flutter, as would be expected with such long-term continuous RAP). These data provide further evidence for NOX2 as a clinical target in AF.

[0049] Gα i / o Inhibitory peptide (Gα i / o Minigenes expressing Gα-ct suppressed ERP shortening and AF in the RAP (Reference 16, the disclosure of which is incorporated herein by reference in its entirety). i2 +Gα o1 10 mg of a plasmid expressing the peptide (under the control of the long-acting UBC promoter) was injected into the PLA. Five control animals also underwent RAP (one injected with a scrambled gene, one as a sham control, and the other controls underwent RAP without thoracotomy). All animals then underwent RAP at 600 bpm (without AV node ablation) for 20 days. Pacing was stopped for 30-60 min every 48 h to assess for persistent AF. Figure 4 shows the Gα i / o We show that -ct significantly delayed the onset of AF in dogs undergoing RAP (p<0.05). This was accompanied by a significant ERP prolongation (Gα i / o These data indicate that parasympathetic nerves contribute to ERP shortening and AF in the RAP, and that Gα i / o These results indicate that IL-1 has beneficial effects on long-term electrical remodeling.

[0050] NOX2 shRNA+Gα i / o The peptide is effective in preventing AF in RAP. NOX2 shRNA+Gα in canine subjects i2 Minigene expressing Gα o1Five months after RAP, the dog did not develop persistent AF. Importantly, unlike dogs receiving chronic NOX2 shRNA, which developed persistent atrial flutter, the animals only showed nonsustained atrial flutter interspersed with episodes of sinus rhythm. These results suggest the efficacy of NOX2 shRNA+Gα in preventing AF in RAP. i / o This shows the synergistic effect of the peptides.

[0051] Both OS and parasympathetic signaling contribute to electrical remodeling in RAP.Furthermore, OS inhibition significantly suppresses parasympathetic proliferation / sprouting in RAP, indicating the close interplay between these mechanisms.In some embodiments, the present specification provides methods and compositions for genetically inhibiting OS and parasympathetic signaling (alone or in combination) to reverse the electrical remodeling established in RAP model and consequently reduce AF.

[0052] In some embodiments, compositions and methods are provided for inhibiting NOX2. Some exemplary methods and compositions for inhibiting NOX2 are described, for example, in U.S. Patent No. 9,932,588, which is incorporated by reference in its entirety. In some embodiments, the present invention provides a method for inhibiting NOX2-mediated signaling events in cells or tissues. These methods include administering one of the isolated nucleic acids comprising modified NOX2 peptide and minigene encoding modified NOX2 peptide to cells or tissues, preferably human cells or tissues, so that after administration, NOX2 peptide inhibits NOX2-mediated signaling events in cells or tissues.

[0053] In some embodiments, compositions and methods for inhibiting NOX2 activity and / or expression are provided.

[0054] In other embodiments, compositions and methods are provided for inhibiting the expression of NOX2.Many methods are known in the art for modifying gene expression in cells, tissues or subjects (e.g., RNAi, antisense RNA, gene therapy, CRISPR, etc.).In some embodiments, nucleic acid is used to regulate the expression of NOX2.

[0055] In some embodiments, this technology provides a method for inhibiting NOX2 activity by administering an antibody or fragment that recognizes, binds to, and inhibits the activity of NOX2. In some embodiments, the antibody is a monoclonal antibody, and in some embodiments, the antibody is a polyclonal antibody. In some embodiments, the antibody is, for example, a human, humanized, or chimeric antibody.

[0056] In some embodiments, the NOX2 inhibitor is a small molecule. In some embodiments, the present invention provides small molecule inhibitors of NOX2. In some embodiments, the present invention provides small molecule drugs or pharmaceutical compounds that are configured to or can inhibit NOX2 activity, function, etc.

[0057] For example, in some embodiments, small interfering RNA (siRNA) is designed to target and degrade NOX2. siRNAs are double-stranded RNA molecules 20-25 nucleotides in length. Although there is no limit to their characteristics, siRNAs are typically 21 nucleotides in length with 2-nt 3' overhangs at both ends. Each strand has a 5' phosphate group and a 3' hydroxyl group. In vivo, this structure is the result of processing by Dicer, an enzyme that converts either long dsRNA or short hairpin RNA (shRNA) into siRNA. However, siRNAs can also be synthesized and exogenously introduced into cells to cause specific knockdown of a gene of interest. Essentially, any gene whose sequence is known can be targeted based on sequence complementarity with appropriately tailored siRNAs. For example, one of skill in the art can synthesize siRNAs (see, e.g., Elbashir, et al., Nature 411:494 (2001); Elbashir, et al. Genes Dev 15:188 (2001); Tuschl T, et al., Genes Dev 13:3191 (1999), which are incorporated by reference in their entireties).

[0058] In some embodiments, RNAi is used to inhibit the expression of NOX2. In some embodiments, RNAi is used to regulate the expression of NOX2. RNAi represents an evolutionarily conserved cellular defense to control the expression of foreign genes in most eukaryotic organisms, including humans. RNAi is usually triggered by double-stranded RNA (dsRNA) and causes sequence-specific degradation of single-stranded target RNA (such as mRNA). The mediator of mRNA degradation is usually a small interfering RNA (siRNA), which is generated from a long strand of dsRNA by enzymatic cleavage in the cell. siRNAs are generally about 21 nucleotides in length (e.g., 21-23 nucleotides in length) and have a base-paired structure characterized by two-nucleotide 3' overhangs. After small RNA or RNAi is introduced into a cell, it is believed that the sequence is delivered to an enzyme complex called RISC (RNA-induced silencing complex). RISC recognizes the target and cleaves it with an endonuclease. It should be noted that when larger RNA sequences are delivered to cells, RNase III enzymes (e.g., Dicer) convert the longer dsRNA into 21-23 nucleotide double-stranded siRNA fragments. In some embodiments, RNAi oligonucleotides are designed to target the junction region of a fusion protein. Chemically synthesized siRNAs have become powerful reagents for genome-wide analysis of mammalian gene function in cultured somatic cells. Beyond their value for validating gene function, siRNAs also hold great potential as gene-specific therapeutics (see, e.g., Tuschl and Borkhardt, Molecular Intervent. 2002;2(3):158-67, incorporated herein by reference).

[0059] In other embodiments, shRNA technology (see, e.g., U.S. Publication No. 2008 / 0025958, which is incorporated herein by reference in its entirety) is utilized to modulate (e.g., inhibit) the expression of NOX2. Small hairpin RNA or short hairpin RNA (shRNA) is a sequence of RNA that forms a tight hairpin turn that can be used to silence gene expression by RNA interference. shRNA utilizes a vector that is introduced into cells and utilizes a U6 promoter so that the shRNA is always expressed. This vector is usually inherited by daughter cells, and gene silencing can be inherited. The shRNA hairpin structure is cleaved into siRNA by the cellular machinery, and the siRNA binds to the RNA-induced silencing complex (RISC). This complex binds to and cleaves the mRNA that matches the siRNA bound to the complex. shRNA is transcribed by RNA polymerase III.

[0060] In some embodiments, provided herein is a short hairpin RNA (shRNA) targeting the NOX2 gene ("NOX2 shRNA"). The shRNA may be a unimolecular RNA comprising a sense sequence, a loop region, and an antisense sequence (sometimes referred to as a first and second region), which together form a hairpin loop structure. Preferably, the antisense and sense sequences are substantially complementary to each other (about 80% or more complementary), and in certain embodiments, the antisense and sense sequences are 100% complementary to each other. In certain embodiments, the antisense and sense sequences are too short to be processed by Dicer, and therefore act via a pathway separate from that of longer double-stranded RNA (e.g., an shRNA (e.g., an sshRNA) having antisense and sense sequences about 16 to about 22 nucleotides in length, e.g., 18 to 19 nucleotides in length). Furthermore, the antisense and sense sequences in the unimolecular RNA of the present invention may be the same length, or may differ in length by less than about 9 bases. The loop may be of any length, but a preferred length is a non-nucleotide linker of 0-4 nucleotides or equivalent length, more preferably a non-nucleotide linker of 2 nucleotides or equivalent length (e.g., a non-nucleotide loop having a length equivalent to 2 nucleotides). In one embodiment, the loop is 5'-UU-3' (rUrU) or 5'-tt-3', where "t" represents deoxythymidine (dTdT). Within any shRNA hairpin, multiple nucleotides are ribonucleotides. In the case of a 0 nucleotide loop, the antisense sequence is directly linked to the sense sequence, and a portion of one or both strands forms the loop. In a preferred embodiment of an shRNA with a 0 nucleotide (nt) loop, the antisense sequence is about 18 or 19 nt, the sense sequence is shorter than the antisense sequence, and one end of the antisense sequence forms the loop.

[0061] Exemplary shRNA hairpins can be configured as either left-handed (L) hairpins (i.e., 5'-antisense-loop-sense-3') or right-handed (R) hairpins (i.e., 5'-sense-loop-antisense-3'). Additionally, shRNAs may have overhangs at either the 5' or 3' end of either the sense or antisense sequence, depending on the hairpin configuration. Preferably, any overhangs, if any, are at the 3' end of the hairpin and consist of 1-6 bases. Overhangs are preferably present in R-type hairpins, with 2 nt overhangs being preferred, and UU or tt overhangs being most preferred.

[0062] Modifications can be added to improve the stability, functionality, and / or specificity of shRNA and minimize immune stimulatory properties.For example, overhangs can be unmodified or can have one or more specificity or stabilizing modifications, such as halogen or O-alkyl modifications at 2' position, or internucleotide modifications, such as phosphorothioate modifications.Overhangs can be ribonucleic acid, deoxyribonucleic acid, or a combination of ribonucleic acid and deoxyribonucleic acid.

[0063] In another non-limiting example of a modification that can be applied to a left-handed hairpin, a 2'-O-methyl modification (or other 2' modifications, including but not limited to, other 2'-O-alkyl modifications) can be added to the nucleotides at positions 15, 17, or 19 from the 5' antisense end of the hairpin, or any two or all three of these positions, as well as to the nucleotides of the loop and to every other nucleotide of the sense sequence except for nucleotides 9, 10, and 11 (also referred to as the 9th, 10th, and 11th nucleotides) from the 5'-most nucleotide of the sense sequence, which must not have modifications that inhibit "slicing" activity. Any single modification or group of modifications described in the preceding sentence can be used alone or in combination with any other modification or group of modifications recited.

[0064] Ui-Tei, K. et al. (Nucl. Acids Res. (2008) 36 (22): 7100-7109) observed that the specificity of siRNAs can be increased by modifying the seed region of one or both strands. Such modifications can be applied to the shRNAs of the present disclosure. In another non-limiting example of a modification that can be applied to a hairpin, nt 1-6 of the antisense sequence and nt 14-19 of the sense sequence can be 2'-O-methylated to reduce off-target effects. In a preferred embodiment, only nt 1-6 are modified from 2'-OH to 2'-H or 2'-O-alkyl.

[0065] Because the sense sequence of shRNA can potentially enter RISC and compete with the antisense (targeting) strand, modifications that prevent phosphorylation of the sense sequence are useful for minimizing off-target signatures. Thus, preferred chemical modifications that prevent phosphorylation of the 5' carbon of the 5'-most nucleotide of the right-handed shRNA of the present invention include, but are not limited to, (1) adding a blocking group (e.g., 5'-O-alkyl) to the 5' carbon, or (2) removing the 5'-hydroxyl group (e.g., 5'-deoxynucleotide) (see, for example, WO2005 / 078094).

[0066] In addition to modifications that increase specificity, modifications that increase stability can also be added. In one embodiment, modifications including 2'-O-alkyl groups (or other 2' modifications) can be added to one or more, preferably all pyrimidines (e.g., C and / or U nucleotides) of the sense sequence. Modifications such as 2'F or 2'-O-alkyl, respectively, of some or all C and U of the sense sequence / region, or loop structures can increase the stability of the shRNA molecule without significantly altering target-specific silencing. It should be noted that although these modifications increase stability, it may be desirable to avoid adding these modification patterns to critical positions within the hairpin to avoid disrupting RNAi (e.g., preventing "slicing" activity).

[0067] In some embodiments of the present invention, shRNA may include additional stabilizing modifications to the phosphate backbone.For example, at least one phosphorothioate, phosphorodithioate, and / or methylphosphonate can replace some or all of the 3'-position phosphate groups of nucleotides of the shRNA backbone, or any specific subset of nucleotides (e.g., any or all pyrimidines in the sense sequence of the oligonucleotide backbone), as well as any overhangs, and / or nucleotides in any loop structures present.These modifications can be used independently or in combination with other modifications disclosed herein.

[0068] Descriptions of modified shRNAs of interest can be found in the following references, all of which are incorporated herein by reference in their entireties: Q. Ge, H. Ilves, A. Dallas, P. Kumar, J. Shorenstein, SA Kazakov, and BH Johnston (2010) Minimal-length short hairpin RNAs: The Relationship of Structure and RNAi Activity. RNA 16(1): 106-17 (Epub Dec. 1, 2009); and Q. Ge, A. Dallas, H. Ilves, J. Shorenstein, MA Behlke, and BH Johnston (2010) Effects of Chemical Modification on the Potency, Serum Stability, and Immunostimulatory Properties of Short shRNAs. RNA 16(1): 118-30 (Epub Nov. 30, 2009).

[0069] Modified shRNAs according to embodiments of the invention can include additional chemical modifications for any of a variety of purposes, including a 3' cap structure (e.g., inverted deoxythymidine), a detectable label (e.g., fluorescent label, mass label, radioactive label, etc.) attached to one or more positions of the shRNA, or other conjugates (e.g., amino acids, peptides, proteins, sugars, carbohydrates, lipids, polymers, nucleotides, polynucleotides, etc.) that can enhance delivery, detection, function, specificity, or stability. Combinations of additional chemical modifications can be used as desired by the user.

[0070] Suitable NOX2 shRNAs include nucleic acids ranging from about 20 nucleotides to about 80 nucleotides in length, with a portion of the nucleic acid having a double-stranded domain ranging from about 15 nucleotides to about 25 nucleotides in length. In some embodiments, the shRNA can include modified bases or a phosphodiester backbone to provide stability to the shRNA in tissues and cells. Exemplary NOX2 shRNAs include SEQ ID NO: 34 (nucleotide sequence in the 5' to 3' direction: CCGCCTATGACTTGGAAATGGATACTCGAGTATCCATTTCCAAGTCATAGGTTTTTG). In some embodiments, an exemplary NOX2 shRNA (or other inhibitory nucleic acid) targets the sequence of SEQ ID NO: 1.

[0071] In some embodiments, antisense nucleic acids (e.g., antisense DNA oligos, antisense RNA oligos) are used to regulate the expression of NOX2. For example, in some embodiments, the expression of NOX2 is inhibited using antisense compounds that specifically hybridize with the nucleic acid NOX2. The specific hybridization of the oligomeric compound with its target nucleic acid prevents the normal function of the nucleic acid. Such regulation of the function of the target nucleic acid by a compound that specifically hybridizes with the target nucleic acid is generally referred to as "antisense". The function of DNA that is interfered with includes replication and transcription. The function of RNA that is interfered with includes, for example, transfer of RNA to a protein translation site, translation of protein from RNA, splicing of RNA to generate one or more mRNA species, and any biological function that RNA may participate in or facilitate, such as catalysis. The overall effect of such interference with the target nucleic acid function is the regulation (e.g., inhibition) of the expression of NOX2.

[0072] In some embodiments, the activity and / or expression of NOX2 is suppressed using the CRISPR / Cas system. As described herein, "CRISPR" (Clustered Regularly Interspaced Short Palindromic Repeats) is a segment of prokaryotic DNA that contains short repeated base sequences. Each repeat sequence is followed by a short segment of "spacer DNA" from previous exposure to bacterial viruses or plasmids. The CRISPR / Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages, conferring a type of acquired immunity. The CRISPR spacer recognizes and cuts these exogenous genetic elements in a manner similar to eukaryotic RNAi. The CRISPR / Cas system has been used for gene editing (adding, disrupting, or changing the sequence of a specific gene) and gene regulation in species throughout the phylogenetic tree. By delivering the Cas9 protein and the appropriate guide RNA into the cell, the genome of an organism can be cut at any location. CRISPR can be used to construct RNA-guided gene editing tools that can modify the genome of a subject. In some embodiments, the CRISPR / Cas system is used to inhibit (e.g., partially or completely) expression of NOX2 in a subject, tissue, or cell. In some embodiments, the CRISPR / Cas system is used to generate (e.g., in a subject, tissue, or cell) NOX2 with reduced activity.

[0073] In some embodiments, agents that disrupt autonomic pathways (e.g., pathways involved in AF) are provided. In some embodiments, the present invention provides compositions and methods for disrupting (e.g., blocking, inhibiting) autonomic pathways. In some embodiments, the present invention provides G protein inhibitors that disrupt autonomic pathways. In some embodiments, delivery of G protein inhibitors that selectively block sympathetic or parasympathetic pathways is provided. In some embodiments, provided herein are compositions and methods for the treatment and prevention of atrial fibrillation that block G protein-coupled receptor-mediated signaling. In some embodiments, the present invention provides compositions and methods using G protein inhibitors that disrupt cardiac autonomic pathways as a treatment for atrial fibrillation. In some embodiments, the present invention provides G protein inhibitors for treating cardiac conditions or disorders (e.g., atrial fibrillation). In some embodiments, the present invention provides inhibitors of G protein function.

[0074] In some embodiments, the G protein inhibitor is a G protein inhibitor peptide. In some embodiments, the present invention provides peptides of any suitable amino acid sequence that can inhibit one or more G proteins. In some embodiments, the peptides provided or encoded by the compositions of the present invention can include any sequence of standard amino acids (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine), or non-standard amino acids (e.g., D-amino acids, chemically or biologically generated derivatives of common amino acids, selenocysteine, pyrrolysine, lanthionine, 2-aminoisobutyric acid, dehydroalanine, etc.). In some embodiments, the G protein inhibitory peptide is an inhibitor of Gα (e.g., GαI, Gαs, Gαq, Gα11, Gα12, Gα13, Gα14, G15, Gαo1, Gα16, etc.), GαI, and / or Gαs. In some embodiments, these peptide sequences block receptor / G protein interactions by mimicking the C-terminus of Gα (e.g., Gαo1), GαI and / or Gαs (e.g., 5 C-terminal amino acids, 6 C-terminal amino acids, 7 C-terminal amino acids, 8 C-terminal amino acids, 9 C-terminal amino acids, 10 C-terminal amino acids, 11 C-terminal amino acids, 12 C-terminal amino acids, 13 C-terminal amino acids, 14 C-terminal amino acids, 15 C-terminal amino acids, 16 C-terminal amino acids, 17 C-terminal amino acids, 18 C-terminal amino acids, 19 C-terminal amino acids, 20 C-terminal amino acids, 30 C-terminal amino acids, 40 C-terminal amino acids, 50 C-terminal amino acids, the complete C-terminal region, etc.).

[0075] In some embodiments, for example, a G protein inhibitory peptide of the invention comprises the C-terminus of Gαi (NCBI Accession No. ACN58588.1; GI:224586986). In some embodiments, for example, a G protein inhibitory peptide of the invention comprises the 11 C-terminal amino acids of Gαi (e.g., amino acid sequence IKNNLKDCGLF (SEQ ID NO:3)). In some embodiments, a G protein inhibitory peptide has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or a range therebetween) sequence identity to SEQ ID NO:3.

[0076] In certain embodiments, a G protein inhibitory peptide of the invention comprises the C-terminus of Gαo1 (see complete sequence at NCBI accession number AAH30027; nucleic acid sequence NM_020988). In some embodiments, for example, a G protein inhibitory peptide of the invention comprises the 11 C-terminal amino acids of Gαi (e.g., amino acid sequence IANNLRGCGLY (SEQ ID NO:4)). In some embodiments, a G protein inhibitory peptide has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or ranges therebetween) sequence identity to SEQ ID NO:4.

[0077] In some embodiments, peptides are provided that competitively inhibit G protein interactions by mimicking the C-terminus of Gα (e.g., GαI, Gαs, Gαq, Gα11, Gα12, Gα13, Gα14, Gα15, Gαo1, Gα16, etc.), GαI, and / or Gαs. In some embodiments, the G protein inhibitory peptide is a fragment of a G protein. In some embodiments, the G protein inhibitory peptide mimics the C-terminus of a G protein (e.g., GαI, Gαs, Gα, Gαo1, etc.) but differs from the wild-type sequence (e.g., different length, mutated amino acids, etc.). In some embodiments, the peptide is a mutant form of a G protein or a fragment thereof. In some embodiments, the peptides provided are mutated sequences of the C-terminus of GαI, Gαs, and / or Gα (e.g., GαI, Gαs, Gαq, Gα11, Gα12, Gα13, Gα14, Gα15, Gαo1, Gα16, etc.). In some embodiments, the G protein inhibitory peptide is provided to the subject as an isolated or purified peptide. In some embodiments, the G protein inhibitory peptide is provided to the subject as a nucleic acid molecule encoding such peptide. In some embodiments, the peptide is optimized to enhance cell permeability (e.g., sequence optimization, sequence tagging, tagging with a small molecule, etc.).

[0078] In some embodiments, the compositions and methods include i and / or Gα o Inhibitory peptides, or Gα i and / or Gα o It contains a nucleic acid encoding an inhibitory peptide. i and / or Gα o The nucleic acid elements encoding the inhibitory peptides are different and consist of at least Gα i and / or Gα o A nucleic acid sequence encoding an inhibitory peptide and a Gα i and / or Gα o The vector includes an element necessary for expression of an inhibitory peptide from the vector. i and / or Gα oNucleic acid sequences encoding inhibitory peptides may be used herein.

[0079] In some embodiments, Gα i and / or Gα o A minigene encoding an inhibitory peptide is provided in a pharmaceutical composition and / or administered to a subject. As used herein, the term "minigene" refers to a minimal gene fragment that does not include one or more elements of the native locus, but contains the elements necessary for expression of a gene product or a portion of a gene product or a synthetic construct. In some instances, a Gα i and / or Gα o The minigene of the inhibitory peptide may not include at least one intron, or a portion thereof. In some examples, the minigene may include at least one intron, or a portion thereof. In some embodiments, the minigene includes at least some regulatory sequence that controls or enhances expression of the minigene transcript. In some examples, the minigene regulatory sequence includes a promoter. Promoters useful in minigenes vary, and the selection of such a minigene promoter is determined by a variety of factors, including the desired expression level of the minigene transcript, the desired control of minigene expression, the desired overall size of the minigene, and the intended use of the minigene, including the subject to which the minigene may be administered. Such minigene promoters include, but are not limited to, native promoters, non-native, heterologous promoters, minimal promoters, minipromoters, constitutive promoters, tissue-specific promoters, inducible promoters, synthetic promoters, and the like.

[0080] In some embodiments, the nucleotide sequence of a minigene of the invention is one of SEQ ID NOs: 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, and 33 (Figure 10). In some embodiments, the nucleotide sequence of a minigene of the invention has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or ranges therebetween) sequence identity to one of SEQ ID NOs: 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, and 33. In some embodiments, the minigene sequence is provided within a vector (e.g., a plasmid, a viral vector, etc.) that is delivered to the subject.

[0081] In some instances, Gα i and / or Gα o The nucleic acid encoding the inhibitory peptide comprises a vector backbone, such as, for example, a polynucleotide backbone of a plasmid. The vector backbones useful in the embodiments herein vary and can be selected based on many factors. A vector can comprise one or more vector-specific elements. By "vector-specific elements" is meant elements used to create, construct, propagate, maintain and / or assay a vector before, during or after the construction of the vector and / or before the use of the vector. Such vector-specific elements include, for example, but are not limited to, vector elements required for the propagation, cloning and selection of the vector when in use, including, but not limited to, origins of replication, multiple cloning sites, prokaryotic promoters, phage promoters, selection markers (e.g., antibiotic resistance genes, encoded enzymatic proteins, encoded fluorescent or chromogenic proteins, etc.). Any convenient vector-specific elements can be used as appropriate in the vectors described herein.

[0082] In some embodiments, the G protein inhibitor is provided from an isolated nucleic acid comprising a minigene, the minigene encoding a modified carboxy-terminal Gα peptide, the peptide blocking an interaction site between a G protein and a G protein-coupled receptor in a cell, such as a human cell. Additionally, the minigene can further comprise one or more of a promoter, a ribosome binding site, a translation start codon, and a translation stop codon. In some embodiments, the minigene encodes a modified carboxy-terminal Gα peptide (e.g., a Gαo1 peptide) having one of the following general formulas: MGX, MX, and MZX, where M is a methionine amino acid residue, G is a glycine amino acid residue, Z is an amino acid residue other than a glycine amino acid residue, and X is a carboxy-terminal Gα peptide comprising an amino acid sequence at the carboxy terminus of a Gα subunit and having the property of binding to a G protein-coupled receptor. In this embodiment, X can comprise at least about 3 contiguous amino acids to at least about 54 contiguous amino acids, at least about 3 contiguous amino acids to at least about 11 contiguous amino acids, and at least about 11 contiguous amino acids. In one embodiment, X comprises 7 contiguous terminal amino acid residues of the carboxy terminus of the Gα subunit. For example, the amino acid sequence of the modified carboxy terminal Gα peptide is one of SEQ ID NOs: 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19 (Figure 9). In some embodiments, the amino acid sequence of the modified carboxy-terminal Gα peptide has at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or ranges therebetween) sequence identity to one of SEQ ID NOs: 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

[0083] Exemplary inhibitors of the present invention include those described in U.S. Patent Publication Nos. 20030162258, 20070231830, and 20070077597, all of which are incorporated herein by reference in their entirety. These references further describe methods for identifying and selecting additional inhibitors. Other G protein inhibitors, such as small molecules, RNAi, siRNA, shRNA, antisense compounds, genetic engineering, and antibodies, are described, for example, in U.S. Patent Nos. 8,518,884; 8,193,151; and 6,559,128, all of which are incorporated herein by reference in their entirety.

[0084] In some embodiments, the methods herein include treating patients with AF undergoing open heart surgery. Postoperative AF occurs in more than one third of patients undergoing cardiac surgery and contributes significantly to surgery-related morbidity. In addition to open heart surgery, more and more surgeons are performing minimally invasive epicardial approach ablation (PVI). To treat existing AF or to prevent postoperative AF, the transgene(s) described herein are injected into the atrium during any of these epicardial procedures.

[0085] In some embodiments, the subject to whom the compositions and / or methods herein are administered suffers from a cardiac condition, such as atrial fibrillation or other conditions described herein. In such embodiments, the compositions and methods herein are used to treat such a condition. In some embodiments, the subject to whom the compositions and / or methods herein are administered is at risk for (e.g., has risk factors for) a cardiac condition, such as atrial fibrillation or other conditions described herein. In such embodiments, the compositions and methods herein are used to prevent such a condition.

[0086] In some embodiments, uptake, expression, and / or delivery of any of the agents administered in the embodiments herein can be enhanced by delivery techniques, devices, and / or methods described in, for example, U.S. Patent No. 6,559,128, U.S. Patent No. 8,193,151, U.S. Patent No. 8,518,884, U.S. Patent No. 9,078,918, U.S. Patent No. 9,932,588, U.S. Patent No. 10,369,360, U.S. Provisional Application No. 62 / 961,514, which are incorporated by reference in their entireties. For example, some embodiments include electroporation of tissue to enhance delivery.

[0087] Various embodiments are described herein for the treatment of atrial fibrillation or cardiac arrhythmias. However, the compositions and methods described herein (e.g., for the treatment of atrial fibrillation or cardiac arrhythmias) can also be used to treat or prevent other cardiac conditions and / or diseases. In some embodiments, the present invention provides a method for treating aortic dissection, cardiac arrhythmias (e.g., atrial cardiac arrhythmias (e.g., atrial premature beats, wandering atrial pacemaker, multiple atrial tachycardias, atrial flutter, atrial fibrillation, etc.), atrioventricular junction arrhythmias (e.g., supraventricular tachycardia, sinoatrial node reentrant tachycardia, paroxysmal supraventricular tachycardia, atrioventricular junctional rhythm, atrioventricular junctional tachycardia, atrioventricular junctional extracomplexes, etc.), atrial ventricular arrhythmias, ventricular arrhythmias (e.g., ventricular premature beats, facilitated idioventricular rhythms, etc.), and the like. In one embodiment, the present invention provides for the treatment or prevention of a cardiac disease or condition selected from the list of cardiac disorders including, but not limited to, chronic myocardial infarction, chronic obstructive pulmonary disease, chronic myocardial infarction, chronic obstructive pulmonary disease, chronic myocardial infarction (COPD), chronic obstructive pulmonary disease ...

[0088] [Example] experiment Example 1 Reversal of electrical remodeling by NOX2 shRNA in dogs undergoing rapid atrial pacing (RAP) If OS leads to the formation / maintenance of electrical remodeling in AF, then inhibition of NOX2 should reverse ERP shortening in dogs with established electrical remodeling.

[0089] Dogs will undergo RAP for 3 weeks, followed by cardioversion into sinus rhythm and injection of NOX2 shRNA. Dogs will be maintained in sinus rhythm for 1 week to allow time for gene expression. RAP will then be resumed and time to AF recurrence will be measured.

[0090] Since both antiarrhythmic drugs and ablation are not very effective in obtaining acute cardioversion of AF, their efficacy is usually measured by the time to recurrence of AF (after the patient has been cardioverted or ablated to sinus rhythm) (References 25, 35, 36, the disclosures of which are incorporated by reference herein in their entireties). The efficacy of the transgene is examined by assessing the time to onset (or recurrence) of AF in a canine model.

[0091] Preparation of the transgene: Express NOX2 shRNA or scrambled shRNA using a plasmid under the control of the polymerase III promoter (U6). Using this promoter, gene expression for several weeks has been obtained.

[0092] Establishment of the RAP model of AF: An atrial pacemaker is implanted via a jugular vein approach (Reference 8; the disclosure of which is incorporated herein by reference in its entirety). After one week, RAP is initiated at 600 beats / min x 3 weeks.

[0093] Open-chest electrophysiological mapping: After 3 weeks of RAP, dogs are defibrillated to sinus rhythm. Open-chest mapping is performed. Effective refractory periods (ERPs) and atrial conduction are assessed (References 8, 10, 37; the disclosures of which are incorporated herein by reference in their entireties).

[0094] Gene injection: After baseline mapping, inject either NOX2 shRNA or scrambled shRNA into both atria.

[0095] Gene injection protocol: Plasmids are diluted in 8 ml saline and injected subepicardially (4 ml into each atrium). Four to six injections are performed to ensure complete coverage of the atrium (0.5-1 ml per injection) as previously described (References 11-12; the disclosures of which are incorporated herein by reference in their entireties). Left atrial injections include the PV, PLA, and right atrial injections include the SVC / RA junction and RA free wall. Gene injection is followed by electroporation using Genetrodes (Harvard Apparatus) as previously described by the inventors (References 11-12,38; the disclosures of which are incorporated herein by reference in their entireties).

[0096] Resumption of RAP: After 1 week in sinus rhythm, RAP is resumed and continued for 6 months (26 weeks) or until onset of AF. Time to reinduction of persistent AF is monitored in all dogs. Pacing is stopped for 30-60 minutes every 48 hours to evaluate for persistent AF. Persistent AF is defined as AF that does not terminate during this time.

[0097] Open-chest mapping: When AF begins to persist, dogs are defibrillated to sinus rhythm and a definitive open-chest study is performed. ERP and conductivity are measured at baseline (References 8-9; the disclosures of which are incorporated herein by reference in their entireties).

[0098] Data Analysis: Electrophysiological analysis: Compare all electrophysiological variables (e.g., ERP, conductivity heterogeneity index, AF duration, etc.) between the different groups. Compare each active gene to its respective control using a Bonferroni corrected t-test. Compare the three active gene groups to each other using ANOVA (followed by a Bonferroni corrected post-hoc t-test) to determine the most effective gene group in reversing electrical remodeling in AF. Calculate effect sizes separately for men and women to obtain estimates of sex differences.

[0099] Uniformity of gene expression is assessed by evaluating immunofluorescence of atrial sections taken from the gene-injected area of ​​the atrium in dogs receiving the FLAG-expressing plasmid.

[0100] Knockdown of NOX2 by shRNA: The percentage of NOX2 knockdown will be evaluated by RT-PCR and Western blotting.

[0101] Inhibition of oxidative damage: Protein carbonyl groups are quantified by a DNPH-based immunoassay (Reference 39; the disclosure of which is incorporated herein by reference in its entirety). 2- The amount of production is assessed by lucigenin chemiluminescence (Reference 14, the disclosure of which is incorporated herein by reference in its entirety). Using appropriate substrates, NOX2 and mitochondrially produced O 2- Measure.

[0102] Inflammation: The open chest approach and / or CpG motifs in naked DNA can cause atrial inflammation (References 40-41, the disclosures of which are incorporated by reference herein in their entireties). Assess atrial inflammation (e.g., neutrophil / macrophage infiltration, apoptosis, etc.).

[0103] Fibrosis: Masson's Trichrome staining is performed to quantify fibrosis.

[0104] Signaling pathways: Measure ROS-activated signaling pathways (e.g., CAMKII, PKC, etc.).

[0105] Example 2 C-terminal Gα i / o Inhibitory peptide (Gα i / o Targeted inhibition of parasympathetic signaling by a minigene expressing .ALPHA.-ct reverses electrical remodeling in the RAP When parasympathetic signaling causes electrical remodeling, Gα i / o -ct reverses ERP shortening and prevents / delays AF re-induction in RAP.

[0106] Dogs were subjected to RAP for 3 weeks, followed by electrical cardioversion to sinus rhythm and transgene (Gα i / o -ct). Dogs are maintained in sinus rhythm for one week to allow time for gene expression. RAP is then resumed and continued for six months (26 weeks) or until the onset of AF. At the final test, ERP is determined. Dogs are administered Gα i / o Inject a minigene expressing Gα-ct (see Table 1) using a plasmid under the control of the long-acting human polyubiquitin C (UBc) promoter. i / o -ct is expressed in the plasmid. This plasmid also has a FLAG tag, which is used as a marker gene to evaluate the uniformity of gene expression. Sympathetic and parasympathetic nerves are stained (References 37, 42; the disclosures of which are incorporated by reference in their entireties) and the expression / activity of autonomic signaling proteins (e.g., PKA, cAMP, etc.) are evaluated.

[0107] [Table 1]

[0108] Example 3 NOX2 shRNA and Gα i / o Administration of -ct in combination reverses electrical remodeling in the RAP.

[0109] OS and parasympathetic signaling act synergistically in the formation of AF, and NOX2 shRNA+Gα i / o -ct reverses ERP shortening more effectively than either gene alone. i / o The combination of -ct with NOX2 shRNA was more effective at suppressing ERP shortening than either gene alone, thus reducing AF.

[0110] Example 4 NOX2 shRNA suppresses electrical remodeling and parasympathetic sprouting in dogs undergoing RAP.

[0111] NOX2 shRNA prevented ERP shortening / AF in seven dogs that underwent RAP, in which the atrium was subepicardially injected with NOX2 shRNA followed by electroporation to facilitate gene transfer to the myocardium. Gene injection and electroporation procedures were limited to the PLA in the first four animals, while in the following three animals, gene injection was also performed in the left atrial free wall, LAA, and right atrium. Eighteen animals that underwent injection of scrambled shRNA or no gene injection were used as controls. Figures 5A and 5B show details of the experimental design for evaluating AF in both short-term (i.e., 4-week RAP) and long-term (i.e., 12-week RAP) periods. After gene injection, animals were subjected to RAP, and the duration of induced AF was then recorded during the period when RAP was discontinued. Figure 5A shows the duration of AF after RAP initiation. Control animals developed persistent AF lasting more than 30 minutes within a median RAP of 4 days (interquartile range (IQR) 4–9 days), whereas animals treated with NOX2 shRNA took a median of 21 days to develop this AF burden (p<0.01). Three animals per group were followed for 12 weeks to assess the development of persistent AF (defined as AF duration >8 hours). Figure 5B shows that control animals took a median of 14 days to develop AF >8 hours. In contrast, NOX2 shRNA animals took a median of 28 days to develop AF >8 hours (p<0.05). Over the entire recorded period, control animals had a median AF duration of 60 minutes (IQR 30–60 minutes), whereas animals treated with NOX2 shRNA had a median AF duration of 0 minutes (IQR 0–2 minutes) (p=0.003). ERPs were significantly longer in dogs treated with NOX2 shRNA versus controls (97 ± 52 ms versus 46 ± 20 ms; p < 0.05). After the final test, NOX2 was measured (PCR, Western blotting) and NGF expression was assessed (PCR) and autonomic nerve staining. NOX2 levels were significantly reduced by NOX2 shRNA by PCR (50% reduction, p < 0.05) and Western blotting.NGF was decreased in the NOX2 shRNA-injected PLAs (approximately 50% knockdown rate; p<0.05). Immunostaining showed that the NOX2 shRNA-injected PLAs did not show thickening of nerve bundles, whereas the RAP controls showed parasympathetic overinnervation (Figure 3). The major ion channel that contributes to ERP shortening in the AF (I. CaL , I K1 , and constitutively active I KAch (I KH In atria injected with NOX2 shRNA, I KH It was found that the amplitude of the AF was significantly decreased (data not shown due to space constraints). Conclusion: NOX2 shRNA prevents RAP-induced ERP shortening, AF, and parasympathetic proliferation. The experiments indicate that oxidative damage-induced parasympathetic proliferation contributes to ERP shortening in AF. Two of the dogs injected with NOX2 shRNA were followed up for 8 months after gene injection. These dogs did not develop AF throughout the entire follow-up period. Cultured atria continuously showed significant NOX2 downregulation.

[0112] Example 5 NOX2 shRNA prevents atrial fibrosis in HF models Oxidative damage caused by NOX2 plays a key role in the formation of AF substrates in HF. This model is well known to induce atrial fibrosis. Experiments were performed during the development of the embodiments herein to demonstrate that targeted inhibition of NOX2 in the atria of HF prevents atrial fibrosis. Three animals were injected subepicardially with 5-10 mg of NOX2 shRNA into the posterior left atrium followed by electroporation. Five animals received injections of pUBc-LacZ (HF control). High frequency ventricular pacing was then performed for 3 weeks at 240 bpm followed by open chest mapping. The left atrium was examined for NOX2 knockdown (PCR, Western blot) and fibrosis incidence (%). AF was significantly reduced (NOX2 shRNA vs. LacZ = 636 ± 151 sec vs. 6 ± 0.6 sec; p < 0.01). There was >50% knockdown of native NOX2 in NOX2 shRNA PLA compared to LacZ-treated dogs (Figure 6; p<0.01). Figure 7 shows that fibrosis (stained in blue, arrows) was significantly reduced in NOX2 shRNA compared to LacZ-injected PLA (8.4±0.5% vs. 18.8±1.5%, p<0.05). Conclusion: NOX2 shRNA reduces atrial fibrosis in HF.

[0113] Example 6 NOX2 shRNA±Gαi / o-ct reverses electrical remodeling in the RAP Gene injections after the onset of persistent / perpetual AF were performed in 4 animals. All dogs first underwent RAP for 2-4 months to induce severe electrical remodeling and persistent AF. Dogs were then injected with the following genes: a) NOX2 shRNA (N=1), b) NOX2 shRNA+Gα i / o -ct (N=2), b) scrambled shRNA (N=1) (Figure 8). Animals receiving scrambled shRNA continued to show AF during the 3-month follow-up period after gene injection. Dogs receiving only NOX2 shRNA continued to show episodes of AF, although they organized into atrial flutter several weeks after gene injection. NOX2 shRNA+Gαi / o Of the two dogs that received -ct, one dog transitioned to atrial flutter several weeks after gene injection, but this dog maintained atrial flutter and did not experience episodes of AF. i / o Another dog that received -ct spontaneously converted to sinus rhythm 2 weeks after gene injection (Figure 8). This dog is still being followed up. i / o Combined or simultaneous targeting of NOX2 shRNA+Gα reverses electrical remodeling in AF. i / o The transition to stable atrial flutter and / or sinus rhythm in -ct treated dogs indicates the existence of synergy between these genes.

[0114] References The following references, some of which are cited by number above, are hereby incorporated by reference in their entireties:

[0115] 1.Calkins H, Kuck KH, Cappato R, et al.2012 HRS / EHRA / ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.Europace 2012;14:528-606. 2.Nademanee K, McKenzie J, Kosar E, et al.A new approach for catheter ablation of atrial fibrillation:mapping of the electrophysiologic substrate.J Am Coll Cardiol 2004;43:2044-53. 3.Nademanee K,Schwab MC,Kosar EM,et al.Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation.Journal of the American College of Cardiology 2008;51:843-9. 4.Estner HL,Hessling G,Ndrepepa G,et al.Electrogram-guided substrate ablation with or without pulmonary vein isolation in patients with persistent atrial fibrillation.Europace 2008;10:1281-7. 5.Rahman F,Kwan GF,Benjamin EJ.Global epidemiology of atrial fibrillation.Nat Rev Cardiol 2016;13:501. 6.Chugh SS,Havmoeller R,Narayanan K,et al.Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease 2010 Study.Circulation 2014;129:837-47. 7.Kirchhof P,Calkins H.Catheter ablation in patients with persistent atrial fibrillation.Eur Heart J 2017;38:20-6. 8.Ng J,Villuendas R,Cokic I,et al.Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation.Circ Arrhythm Electrophysiol 2011;4:388-96. 9.Koduri H,Ng J,Cokic I,et al.Contribution of fibrosis and the autonomic nervous system to atrial fibrillation electrograms in heart failure.Circ Arrhythm Electrophysiol 2012;5:640-9. 10.Arora R,Ng J,Ulphani J,et al.Unique autonomic profile of the pulmonary veins and posterior left atrium.J Am Coll Cardiol 2007;49:1340-8. 11.Kunamalla A,Ng J,Parini V,et al.Constitutive Expression of a Dominant-Negative TGF-beta Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate.Circ Res 2016;119:69-82. 12.Aistrup GL,Cokic I,Ng J,et al.Targeted nonviral gene-based inhibition of Galpha(i / o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation.Heart Rhythm 2011;8:1722-9. 13.Avitall B,Bi J,Mykytsey A,Chicos A.Atrial and ventricular fibrosis induced by atrial fibrillation:evidence to support early rhythm control.Heart Rhythm 2008;5:839-45. 14.Kim YM,Guzik TJ,Zhang YH,et al.A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005;97:629-36. 15.Arora R.Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation:implications for therapies targeting the atrial autonomic nervous system.Circ Arrhythm Electrophysiol 2012;5:850-9. 16.Yoo S GG,Wren L,Aistrup G,Ng J,Gordon D,Passman R,Knight B,Goldberger J,Arora R.Selective inhibition of parasympathetic nerve signaling by novel C-terminal Gαi / o peptides prevents electrical remodeling induced atrial fibrillation Heart Rhythm 2016;13:S200. 17.Camm AJ.Hopes and disappointments with antiarrhythmic drugs.Int J Cardiol 2017;237:71-4. 18.Ben Morrison T,Jared Bunch T,Gersh BJ.Pathophysiology of concomitant atrial fibrillation and heart failure:implications for management.Nat Clin Pract Cardiovasc Med 2009;6:46-56. 19.Gillinov AM,Saltman AE.Ablation of atrial fibrillation with concomitant cardiac surgery.Semin Thorac Cardiovasc Surg 2007;19:25-32. 20.Rahman F,Kwan GF,Benjamin EJ.Global epidemiology of atrial fibrillation.Nat Rev Cardiol 2014;11:639-54. 21.Guerra F,Matassini MV,Scappini L,Urbinati A,Capucci A.Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation:systematic review and meta-analysis.Expert Rev Cardiovasc Ther 2014;12:1067-75. 22.Naccarelli GV,Kowey PR.The role of dronedarone in the treatment of atrial fibrillation / flutter in the aftermath of PALLAS.Curr Cardiol Rev 2014;10:303-8. 23.Andrade JG,Khairy P,Guerra PG,et al.Efficacy and safety of cryoballoon ablation for atrial fibrillation:a systematic review of published studies.Heart Rhythm 2011;8:1444-51. 24.Providencia R,Marijon E,Combes S,et al.Higher contact-force values associated with better mid-term outcome of paroxysmal atrial fibrillation ablation using the SmartTouch catheter.Europace 2014. 25.Narayan SM,Baykaner T,Clopton P,et al.Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone:extended follow-up of the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation).J Am Coll Cardiol 2014;63:1761-8. 26.Haissaguerre M,Hocini M,Denis A,et al.Driver domains in persistent atrial fibrillation.Circulation 2014;130:530-8. 27.Schotten U,Verheule S,Kirchhof P,Goette A.Pathophysiological mechanisms of atrial fibrillation: a translational appraisal.Physiol Rev 2011;91:265-325. 28.Zsebo K,Yaroshinsky A,Rudy JJ,et al.Long-term effects of AAV1 / SERCA2a gene transfer in patients with severe heart failure:analysis of recurrent cardiovascular events and mortality.Circ Res 2014;114:101-8. 29.Jessup M,Greenberg B,Mancini D,et al.Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease(CUPID):a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.Circulation 2011;124:304-13. 30.Jaski BE,Jessup ML,Mancini DM,et al.Calcium upregulation by percutaneous administration of gene therapy in cardiac disease(CUPID Trial),a first-in-human phase 1 / 2 clinical trial.Journal of cardiac failure 2009;15:171-81. 31.Chung ES,Miller L,Patel AN,et al.Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients:the STOP-HF randomized Phase II trial.Eur Heart J 2015;36:2228-38. 32.Penn MS,Mendelsohn FO,Schaer GL,et al.An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.Circ Res 2013;112:816-25. 33.Su CH,Wu YJ,Wang HH,Yeh HI.Nonviral gene therapy targeting cardiovascular system.Am J Physiol Heart Circ Physiol 2012;303:H629-38. 34.Bikou O,Thomas D,Trappe K,et al.Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.Cardiovasc Res 2011;92:218-25. 35.Page RL,Connolly SJ,Crijns HJ,et al.Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation(from the ATHENA trial).Am J Cardiol 2011;107:1019-22. 36.Boersma LV,van der Voort P,Debruyne P,et al.Multielectrode Pulmonary Vein Isolation Versus Single Tip Wide Area Catheter Ablation for Paroxysmal Atrial Fibrillation:A Multinational Multicenter Randomized Clinical Trial.Circ Arrhythm Electrophysiol 2016;9:e003151. 37.Arora R,Ulphani JS,Villuendas R,et al.Neural substrate for atrial fibrillation:implications for targeted parasympathetic blockade in the posterior left atrium.Am J Physiol Heart Circ Physiol 2008;294:H134-44. 38.Aistrup GL,Villuendas R,Ng J,et al.Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation.Cardiovasc Res 2009;83:481-92. 39.Wehr NB,Levine RL.Quantification of protein carbonylation.Methods Mol Biol 2013;965:265-81. 40.Zakkar M,Ascione R,James AF,Angelini GD,Suleiman MS.Inflammation,oxidative stress and postoperative atrial fibrillation in cardiac surgery.Pharmacol Ther 2015;154:13-20. 41.Hyde SC,Pringle IA,Abdullah S,et al.CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression.Nature biotechnology 2008;26:549-51. 42.Ulphani JS,Arora R,Cain JH,et al.The ligament of Marshall as a parasympathetic conduit.Am J Physiol Heart Circ Physiol 2007;293:H1629-35. 43.Soucek R,Thomas D,Kelemen K,et al.Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant.Heart Rhythm 2012;9:265-72. 44.Trappe K,Thomas D,Bikou O,et al.Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3:a pre-clinical pilot study.Eur Heart J 2013;34:147-57. 45. Shin Yoo, Anna Pfenniger, Jacob Hoffman, Wenwei Zhang, Jason Ng, Amy Burrell, David A. Johnson, Georg Gussak, Trent Waugh, Suzanne Bull, Brandon Benefield, Bradley P. Knight, Rod Passman, J. Andrew Wasserstrom, Gary L. Aistrup, Rishi Arora. Disruption of NOX2-dependent Oxidative Injury with a Targeted Gene-Therapy Approach Prevents Atrial Fibrillation in a Canine Model.doi:https: / / doi.org / 10.1101 / 765008 https: / / t.co / NG1la43U5i#biorxiv_physio array SEQ ID NO:1 (Exemplary NOX2 target sequence) - TATCCATTTCCAAGTCATAGG SEQ ID NO:3 (an exemplary Gα i Inhibitory peptide; Gα i2 (11 amino acids at the C-terminus of the subunit) - IKNNLKDCGLF SEQ ID NO:4 (Gα o Inhibitory peptide; Gα o1 (11 amino acids at the C-terminus of the subunit) - IANNLRGCGLY SEQ ID NOs: 5-19 (Exemplary G Protein Inhibitory Peptides) - FIG. SEQ ID NOs: 20-33 (exemplary minigenes encoding G protein inhibitory peptides) - FIG. SEQ ID NO:34 (Exemplary NOX2 shRNA) - CCGCCTATGACTTGGAAATGGATACTCGAGTATCCATTTCCAAGTCATAGGTTTTTG [Brief description of the drawings]

[0116] [Figure 1] RAP results in increased nerve hypertrophy and sprouting of parasympathetic fibers. [Diagram 2] Chronic expression of NOX2 shRNA prevents AF in RAP. [Diagram 3] NOX2 shRNA prevents neuronal hyperplasia and parasympathetic sprouting in the RAP. [Figure 4] Gαi / o minigene delays time to onset of AF in RAP. [Figure 5A] NOX2 shRNA prevents the development of persistent AF. In short-term studies, animals treated with NOX2 shRNA developed significantly shorter AF, with a delay in the onset of persistent AF of >30 minutes. For controls, N=3-12; for NOX2 shRNA, n=3-5. [Figure 5B]NOX2 shRNA prevents the development of persistent AF. In our long-term study, gene infusion of NOX2 shRNA prevented the onset of persistent AF for longer than 8 hours. In A and B, control, n=3-12, NOX2 shRNA, n=3-7. Data are means ± SEM. Significant differences by log-rank test are shown on the graph. [Figure 6] Decreased NOX2 expression in NOX2 shRNA-transfected atria. [Figure 7] Reduction of atrial fibrosis by NOX2 shRNA. [Figure 8] NOX2 shRNA±Gαi / o converts AF to atrial flutter or synchrony. For discussion, see text. [Figure 9] Exemplary amino acid sequences of modified carboxy-terminal Gα peptides. [Figure 10] Nucleotide sequences of exemplary minigenes of the present invention.

Claims

1. In the manufacture of a medicament for reversing electrical remodeling associated with atrial fibrillation in a subject, (a) an inhibitor of NADPH oxidase 2 (NOX2) gene expression, comprising a small hairpin RNA (shRNA) comprising a nucleic acid set forth in SEQ ID NO: 34; (b) (i) Gα as shown in SEQ ID NO:3 i a nucleic acid encoding an inhibitory peptide, and / or (ii) Gα as shown in SEQ ID NO:4 o and a nucleic acid encoding an inhibitory peptide.

2. (a) an inhibitor of NADPH oxidase 2 (NOX2) gene expression, comprising a small hairpin RNA (shRNA) comprising a nucleic acid set forth in SEQ ID NO: 34; and (b) Gα as shown in SEQ ID NO:3 i a nucleic acid encoding an inhibitory peptide, and / or (ii) Gα as shown in SEQ ID NO:4 o A pharmaceutical composition for reversing electrical remodeling associated with atrial fibrillation in a subject, comprising a nucleic acid encoding an inhibitory peptide.

3. Gα i Nucleic acid encoding an inhibitory peptide and Gα o The pharmaceutical composition of claim 2, comprising both a nucleic acid encoding an inhibitory peptide.

4. The Gα i The nucleic acid encoding the inhibitory peptide and the Gα o The pharmaceutical composition according to claim 3, comprising a nucleic acid encoding an inhibitory peptide in a ratio of 1:10 to 10:

1.

5. The Gα i The nucleic acid encoding the inhibitory peptide and the Gα o The pharmaceutical composition of claim 4, comprising a nucleic acid encoding an inhibitory peptide in a 1:1 ratio.

Citation Information

Patent Citations

  • Compositions and methods for treating atrial fibrillation

    US20120329718A1

  • Inhibition of oxidative stress in atrial fibrillation

    US20150203852A1